It is hoped that by coupling trastuzumab (Herceptin; Genentech/Roche) — a humanized monoclonal antibody (mAb) specific for the human epidermal growth factor receptor 2 (HER2; also known as ERBB2 ...

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

This image accompanied the report "Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site," by J. Bostrom et. al. appearing in the March 20, 2009 issue of ...

The monoclonal antibody against HER2, trastuzumab (Herceptin), ® has become an important player in the treatment of patients with HER2-positive breast cancer. Both in the metastatic and adjuvant ...

Too many copies of the HER2 gene or its overexpression appeared to cause an especially aggressive form of the disease. By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...

Then reality hit: Many obstacles stood in the path toward using monoclonal antibodies as standard therapy. With Food and Drug Administration approval of Herceptin for certain breast cancer tumors last ...

But the situation is different with cancer drugs. Herceptin, for example, is given at doses of 500 mg or more. “A concentrated antibody formulation like 100 mg/ml would take at least 5 ml to ...

Herceptin is one of a new class of drugs called monoclonal antibodies -- lab-engineered antibodies designed to mimic the body's own immune system response. Herceptin targets the HER2 protein ...

Rwanda is set to become home to Africa’s first manufacturing plant for eye care products and monoclonal antibodies targeting cancer, with completion expected by 2026, according to Dr. Menghis Bairu, ...